APA (7th ed.) Citation

D, W., B, F., Z, P., D, Y., M, H., M, L., . . . X, X. (2021). Tocilizumab in patients with moderate or severe COVID-19: A randomized, controlled, open-label, multicenter trial. Frontiers of medicine, 15(3), 486. https://doi.org/10.1007/s11684-020-0824-3

Chicago Style (17th ed.) Citation

D, Wang, et al. "Tocilizumab in Patients with Moderate or Severe COVID-19: A Randomized, Controlled, Open-label, Multicenter Trial." Frontiers of Medicine 15, no. 3 (2021): 486. https://doi.org/10.1007/s11684-020-0824-3.

MLA (9th ed.) Citation

D, Wang, et al. "Tocilizumab in Patients with Moderate or Severe COVID-19: A Randomized, Controlled, Open-label, Multicenter Trial." Frontiers of Medicine, vol. 15, no. 3, 2021, p. 486, https://doi.org/10.1007/s11684-020-0824-3.